Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy

被引:49
|
作者
Sun, Yating [1 ]
Zhao, Yarong [1 ]
Teng, Shanshan [1 ]
Hao, Fei [1 ]
Zhang, Huan [1 ]
Meng, Fanchao [1 ]
Zhao, Xiuting [1 ]
Zheng, Xiaolong [1 ]
Bi, Ye [1 ]
Yao, Yicheng [2 ]
Lee, Robert J. [1 ,3 ]
Teng, Lesheng [1 ]
机构
[1] Jilin Univ, Sch Life Sci, 2699 Qianjin Ave, Changchun, Jilin, Peoples R China
[2] Acalanes High Sch, Lafayette, CA USA
[3] Ohio State Univ, Coll Pharm, Div Pharmaceut, 500 W 12Th Ave, Columbus, OH 43210 USA
来源
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
folic acid; human serum albumin; nanoparticles; cabazitaxel; folic acid receptor; CONJUGATED NANOPARTICLES; FOLATE; DOCETAXEL; RESISTANT; DELIVERY; AGENT;
D O I
10.2147/IJN.S181296
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: We previously developed cabazitaxel (CTX)-loaded human serum albumin nanoparticles (NPs-CTX) via a self-assembly method, and these NPs showed efficacy in prostate cancer therapy. Many studies have shown that the levels of folic acid (FA) receptor on the surface of various tumor cells are high. Therefore, FA-modified NPs-CTX may have enhanced antitumor effects compared with unmodified NPs-CTX. Methods: NPs-CTX were first prepared via self-assembly, and FA was conjugated on the surface of NPs-CTX through the -NH2 groups of the NPs to produce FA-NPs-CTX. The FA-NPs-CTX were evaluated in tumor cells with high FA receptor (FR) expression in vitro and in vivo. Results: Both NPs-CTX and FA-NPs-CTX exhibited good stability and morphology. Drug release from the NPs was not affected by FA conjugation. Compared with CTX dissolved in a mixture of Tween 80 and 13% ethanol (w/w) at a ratio of 1: 4 (v/v) (Tween-CTX), the two nanoformulations had lower lytic activity against normal red blood cells. However, FA-NPs-CTX showed greater inhibition of tumor cells with overexpressed FR, compared with NPs-CTX, in the cytotoxicity experiments. Moreover, the cellular uptake of FA-NPs-CTX was enhanced through FR-mediated endocytosis in HeLa cells in vitro and HeLa xenograft tumors in vivo. Although Tween-CTX exhibited tumor growth inhibition similar to FA-NPs-CTX in vivo, this inhibition also caused adverse side effects; the median lethal dose (LD50) of Tween-CTX to mice was 5.68 mg/kg, while FA-NPs-CTX-treated mice survived at doses exceeding 400 mg/kg. Conclusion: The results showed that FA-NPs-CTX caused inhibition of tumor growth in a manner similar to that of Tween-CTX; however, the safety and tolerability of CTX were greatly improved by FA conjugation compared with those of Tween-CTX. In summary, FA-NPs-CTX have great potential in CTX delivery, and this formulation is a promising candidate for the treatment of cancers with high FR levels.
引用
收藏
页码:135 / 148
页数:14
相关论文
共 50 条
  • [41] Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers
    Liu, Lisha
    Bi, Yunke
    Zhou, Muru
    Chen, Xinli
    He, Xi
    Zhang, Yujie
    Sun, Tao
    Ruan, Chunhui
    Chen, Qingjun
    Wang, Hao
    Jiang, Chen
    ACS APPLIED MATERIALS & INTERFACES, 2017, 9 (08) : 7424 - 7435
  • [42] DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid-Targeted 177Lu-Radionuclide Tumor Therapy in Mice
    Mueller, Cristina
    Struthers, Harriet
    Winiger, Christian
    Zhernosekov, Konstantin
    Schibli, Roger
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (01) : 124 - 131
  • [43] Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy
    Muralidhar, Anusha
    Gamat-Huber, Melissa
    Vakkalanka, Sita
    McNeel, Douglas G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [44] Hybrid folic acid-conjugated gold nanorods-loaded human serum albumin nanoparticles for simultaneous photothermal and chemotherapeutic therapy
    Encinas-Basurto, David
    Ibarra, Jaime
    Juarez, Josue
    Pardo, Alberto
    Barbosa, Silvia
    Taboada, Pablo
    Valdez, Miguel A.
    MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2018, 91 : 669 - 678
  • [45] A Carrier-Free Folate Receptor-Targeted Ursolic Acid/Methotrexate Nanodelivery System for Synergetic Anticancer Therapy
    Lan, Jin-Shuai
    Qin, Yan-Hong
    Liu, Li
    Zeng, Rui-Feng
    Yang, Yang
    Wang, Kai
    Ding, Yue
    Zhang, Tong
    Ho, Rodney J. Y.
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2021, 16 : 1775 - 1787
  • [46] Development of In Situ Gelling Meloxicam-Human Serum Albumin Nanoparticle Formulation for Nose-to-Brain Application
    Katona, Gabor
    Sipos, Bence
    Budai-Szucs, Maria
    Balogh, Gyorgy Tibor
    Veszelka, Szilvia
    Grof, Ilona
    Deli, Maria A.
    Volk, Balazs
    Szabo-Revesz, Piroska
    Csoka, Ildiko
    PHARMACEUTICS, 2021, 13 (05)
  • [47] Enhanced Delivery of Retinoic Acid to Breast Cancer Cells by Folate Receptor-Targeted Folic Acid-Conjugated Glutenin Nanoparticles for Promising Treatment of Breast Cancer
    Rajeshkumar, Raja Rajeswari
    Pavadai, Parasuraman
    Panneerselvam, Theivendren
    Pandian, Sureshbabu Ram Kumar
    Kumar, A. Santhana Krishna
    Maszczyk, Piotr
    Babkiewicz, Ewa
    Kabilan, Shanmugampillai Jeyarajaguru
    Kunjiappan, Selvaraj
    JOURNAL OF POLYMERS AND THE ENVIRONMENT, 2024, 32 (05) : 2120 - 2139
  • [48] Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy
    Edelman, Ravit
    Assaraf, Yehuda G.
    Levitzky, Inna
    Shahar, Tal
    Livney, Yoav D.
    ONCOTARGET, 2017, 8 (15) : 24337 - 24353
  • [49] Scavenger receptor-targeted photodynamic therapy of J774 tumors in mice: Tumor response and concomitant immunity.
    Hamblin, MR
    O'Donnell, DA
    Huzaira, M
    Zahra, T
    LASER TISSUE INTERACTION XIII: PHOTOCHEMICAL, PHOTOTHERMAL, AND PHOTOMECHANICAL, 2002, 4617 : 1 - 10
  • [50] Self-Assembling Derivative of Hydrocortisone as Glucocorticoid Receptor-Targeted Nanotherapeutics for Synergistic, Combination Therapy against Colorectal Tumor
    Sridharan, Kathyayani
    Rathore, Bhowmira
    Yousuf, Md
    Rachamalla, Hari Krishna Reddy
    Jinka, Sudhakar
    Jaggarapu, Madhan Mohan Chandra Sekhar
    Banerjee, Rajkumar
    MOLECULAR PHARMACEUTICS, 2021, 18 (03) : 1208 - 1228